Quarterly report pursuant to Section 13 or 15(d)

Licensing and Other Arrangements - Takeda (Details)

v3.23.1
Licensing and Other Arrangements - Takeda (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended
Nov. 01, 2006
Nov. 30, 2020
Feb. 28, 2009
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Licensing and other arrangements            
Revenue from contracts with customers         $ 2,750  
Takeda | Collaboration Agreement            
Licensing and other arrangements            
Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones       $ 16,000    
Revenue from contracts with customers   $ 2,000   0 $ 800  
Contract assets       0   $ 0
Contract liabilities       0   0
Capitalized contract costs       $ 0   $ 0
Takeda | Collaboration Agreement | TAK-079            
Licensing and other arrangements            
Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones $ 19,000          
Royalty payment period 13 years 6 months          
Royalty payment period from the first commercial sale of each royalty-bearing discovery product 12 years          
Takeda | Collaboration Agreement | Other antibodies            
Licensing and other arrangements            
Maximum eligible milestone payments receivable per discovery product candidate     $ 3,300      
Royalty payment period     10 years